This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View
by Zacks Equity Research
Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.
Apple (AAPL) Halts Smartwatch Sales Ban Amid Patent Dispute
by Zacks Equity Research
Apple (AAPL) wins a temporary reprieve in the patent battle over its smartwatches, pausing an import ban amid a legal clash with Masimo over medical tech.
Zacks Investment Ideas feature highlights: Nike, Apple, Masimo and Micron Technology
by Zacks Equity Research
Nike, Apple, Masimo and Micron Technology are part of the Zacks Investment Ideas article.
Famed Santa Claus Rally Begins: Stocks to Watch
by Bryan Hayes
Today marks the final trading day before Christmas and is also the first day of a period known as the Santa Claus Rally.
Masimo's (MASI) Stork Baby Monitoring System Approved by FDA
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Masimo's (MASI) ORi Favored by Study for PaO2 Information
by Zacks Equity Research
Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
Masimo's (MASI) W1 Medical Watch to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the latest FDA approval is expected to provide greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily.
Masimo's (MASI) Latest Tie-Up to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) latest joint effort is likely to enable real-time continuous monitoring with a tailored view of the patient's vitals while keeping them mobile during critical recovery periods.
Company News for Nov 9, 2023
by Zacks Equity Research
Companies in The News Are: RL,OXY,AKAM,MASI
Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.
Compared to Estimates, Masimo (MASI) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -2.46% and 24.29%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Philips (PHG) Aids Clinicians With New Monitoring Solution
by Zacks Equity Research
Philips (PHG) launches Visual Patient Avatar to help anesthesiologists with situational awareness in operating rooms, boosting their clinical confidence.
Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi
by Zacks Equity Research
Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.
Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark
by Zacks Equity Research
Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.
Philips (PHG) Expands Mobile C-arm Portfolio With Zenition 30
by Zacks Equity Research
Philips (PHG) expands its mobile C-arm lineup with Zenition 30, which provides surgeons with more control and customization.
Masimo's (MASI) Inks Agreement to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.
Masimo's (MASI) Stork Baby Monitor Now Available Across U.S.
by Zacks Equity Research
The latest U.S. availability of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients
by Zacks Equity Research
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.
Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise
by Zacks Equity Research
Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.
Masimo (MASI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Masimo (MASI) Q2 Earnings Miss Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of -27.91% and 0.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 171.43% and 4.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?